861 related articles for article (PubMed ID: 28805160)
1. Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy.
Yu SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Thyroid; 2017 Sep; 27(9):1185-1193. PubMed ID: 28805160
[TBL] [Abstract][Full Text] [Related]
2. Serum Immunoglobulin G4 levels are elevated in patients with Graves' ophthalmopathy.
Bozkirli E; Bakiner OS; Ersozlu Bozkirli ED; Eksi Haydardedeoglu F; Sizmaz S; Torun AI; Ertorer ME
Clin Endocrinol (Oxf); 2015 Dec; 83(6):962-7. PubMed ID: 25400133
[TBL] [Abstract][Full Text] [Related]
3. Ocular Manifestations and Clinical Implications of Serum Immunoglobulin G4 Levels in Graves' Ophthalmopathy Patients.
Luo B; Yuan X; Wang W; Zhang J; Liu R; Hu W; Qi X; Xiang N; Chen L
Ocul Immunol Inflamm; 2022 Apr; 30(3):580-587. PubMed ID: 33054491
[TBL] [Abstract][Full Text] [Related]
4. [Autoantibodies, immunoglobulins and cytokine profile in patients with graves' disease and Graves' orbitopathy].
Sviridenko NY; Bessmertnaya EG; Belovalova IM; Mikheenkov AA; Sheremeta MS; Nikankina LV; Malysheva NM
Probl Endokrinol (Mosk); 2020 Oct; 66(5):15-23. PubMed ID: 33369369
[TBL] [Abstract][Full Text] [Related]
5. IgG4 as a Biomarker in Graves' Orbitopathy.
Olejarz M; Szczepanek-Parulska E; Dadej D; Sawicka-Gutaj N; Domin R; Ruchała M
Mediators Inflamm; 2021; 2021():5590471. PubMed ID: 34220335
[TBL] [Abstract][Full Text] [Related]
6. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
Woo YJ; Jang SY; Lim TH; Yoon JS
Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of serum immunoglobulin G4 in glucocorticoid therapy of Graves' ophthalmopathy.
Li Y; Luo B; Zhang J; Zhou X; Shao S; Xu W; Yang Y; Yuan G
Clin Endocrinol (Oxf); 2021 Oct; 95(4):657-667. PubMed ID: 33938028
[TBL] [Abstract][Full Text] [Related]
8. Nicotinamide phosphoribosyltransferase leukocyte overexpression in Graves' opthalmopathy.
Sawicka-Gutaj N; Budny B; Zybek-Kocik A; Sowiński J; Ziemnicka K; Waligórska-Stachura J; Ruchała M
Endocrine; 2016 Aug; 53(2):497-504. PubMed ID: 26767650
[TBL] [Abstract][Full Text] [Related]
9. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
Marinò M; Rotondo Dottore G; Ionni I; Lanzolla G; Sabini E; Ricci D; Sframeli A; Mazzi B; Menconi F; Latrofa F; Vitti P; Marcocci C; Chiovato L
J Endocrinol Invest; 2019 Apr; 42(4):471-480. PubMed ID: 30132285
[TBL] [Abstract][Full Text] [Related]
10. Serum immunoglobulin G4 levels and Graves' disease phenotype.
Martin CS; Sirbu AE; Betivoiu MA; Florea S; Barbu CG; Fica SV
Endocrine; 2017 Feb; 55(2):478-484. PubMed ID: 27819113
[TBL] [Abstract][Full Text] [Related]
11. [Distribution of IgG subclasses of TgAb and TPOAb in sera from patients with Graves' disease, Graves' disease plus Hashimoto's thyroiditis and Hashimoto's thyrotoxicosis].
Yuan S; Yu N; Gao Y; Huang W; He Y; Dong B; Lu G; Li M; Cai X; Peng D; Wang Y; Li T; Huang Y; Gao Y; Guo X; Shi B
Zhonghua Yi Xue Za Zhi; 2014 Jan; 94(2):110-4. PubMed ID: 24721350
[TBL] [Abstract][Full Text] [Related]
12. Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves' orbitopathy.
Nicolì F; Lanzolla G; Mantuano M; Ionni I; Mazzi B; Leo M; Sframeli A; Posarelli C; Maglionico MN; Figus M; Nardi M; Marcocci C; Marinò M
J Endocrinol Invest; 2021 Mar; 44(3):581-585. PubMed ID: 32648002
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for Graves' Orbitopathy in surgical patients-Results of a 10-year retrospective study with review of the literature.
Tabriz N; Gruben A; Uslar V; Weyhe D
Endocrinol Diabetes Metab; 2021 Jan; 4(1):e00210. PubMed ID: 33532627
[TBL] [Abstract][Full Text] [Related]
14. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
[TBL] [Abstract][Full Text] [Related]
15. IGF1 deficiency in newly diagnosed Graves' disease patients.
Martin S; Sirbu A; Betivoiu M; Florea S; Barbu C; Fica S
Hormones (Athens); 2015; 14(4):651-9. PubMed ID: 26188228
[TBL] [Abstract][Full Text] [Related]
16. Serum concentrations of adiponectin and resistin in hyperthyroid Graves' disease patients.
Sieminska L; Niedziolka D; Pillich A; Kos-Kudla B; Marek B; Nowak M; Borgiel-Marek H
J Endocrinol Invest; 2008 Sep; 31(9):745-9. PubMed ID: 18997483
[TBL] [Abstract][Full Text] [Related]
17. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy.
Lytton SD; Ponto KA; Kanitz M; Matheis N; Kohn LD; Kahaly GJ
J Clin Endocrinol Metab; 2010 May; 95(5):2123-31. PubMed ID: 20237164
[TBL] [Abstract][Full Text] [Related]
18. Elevated serum immunoglobulin G4 levels in patients with Graves' disease and their clinical implications.
Takeshima K; Inaba H; Furukawa Y; Nishi M; Yamaoka H; Miyamoto W; Ota T; Doi A; Kawashima H; Ariyasu H; Wakasaki H; Furuta H; Nakao T; Sasaki H; Akamizu T
Thyroid; 2014 Apr; 24(4):736-43. PubMed ID: 24256421
[TBL] [Abstract][Full Text] [Related]
19. TSH receptor antibody titers measured with a third-generation assay did not reflect the activity of Graves' ophthalmopathy in untreated Japanese Graves' disease patients.
Mukasa K; Yoshimura Noh J; Kouzaki A; Ohye H; Kunii Y; Watanabe N; Yoshihara A; Matsumoto M; Suzuki M; Ito K
Endocr J; 2016; 63(2):151-7. PubMed ID: 26581710
[TBL] [Abstract][Full Text] [Related]
20. Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study.
De Bellis A; Conzo G; Cennamo G; Pane E; Bellastella G; Colella C; Iacovo AD; Paglionico VA; Sinisi AA; Wall JR; Bizzarro A; Bellastella A
Endocrine; 2012 Apr; 41(2):320-6. PubMed ID: 22169963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
